ASCL2 and neoplasm: Although no significant differences in tumor burden were found between the cohorts of ApcMin/+and ApcMin/+;Ascl2 CKO mice (Fig. 4E, F), the survival of the ApcMin/+;Ascl2 CKO mice were surprisingly longer than that of the control mice (Fig. 4G).